Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470613 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Infusion of SGT-53 to Treat Solid Tumors
A Phase 1 study, sponsored by SynerGene Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00470613 is a Phase 1 study that has completed, run by SynerGene Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT00470613, a Phase 1 study, has completed, sponsored by SynerGene Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a Phase Ib study as a continuation of the original Phase I protocol. The purpose of this Phase Ib study is to evaluate the safety of a single course of SGT-53 in combination with docetaxel and determine the recommended Phase II doses of SGT-53 and docetaxel in combination for evaluation in subsequent clinical studies for the treatment of solid tumors.
Interventions
- GENETIC SGT-53
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-02 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470613
The ClinicalTrials.gov registry entry for NCT00470613 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SynerGene Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGT-53 is the first listed.
NCT00470613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00470613 about?
NCT00470613 is a clinical study titled "Safety Study of Infusion of SGT-53 to Treat Solid Tumors". This is a Phase Ib study as a continuation of the original Phase I protocol. The purpose of this Phase Ib study is to evaluate the safety of a single course of SGT-53 in combination with docetaxel and determine the recommended Phase II doses of SGT-53 and docetaxel in combination for evaluation in s...
What is the current status of trial NCT00470613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-02. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00470613?
The interventions under investigation include: SGT-53 (GENETIC).
Who is sponsoring clinical trial NCT00470613?
This trial is sponsored by SynerGene Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.